STOCK TITAN

Lineage Cell Therapeutics (LCTX) Stock News

LCTX NYSE

Lineage Cell Therapeutics, Inc. develops allogeneic, or “off-the-shelf,” cell therapies for serious medical conditions using its AlloSCOPE cell differentiation and expansion platform. Its pipeline includes OpRegen, also known as RG6501, for geographic atrophy secondary to age-related macular degeneration; OPC1 for spinal cord injury; ReSonance, or ANP1, for hearing loss; and COR1 for corneal endothelial disease.

Recurring company news covers clinical data presentations, preclinical program launches, manufacturing and platform updates, research collaborations, milestone activity, financial results, business updates, and scientific governance. Updates frequently connect Lineage’s cell transplant programs with ophthalmology, neurology, auditory disease, and other non-oncology therapeutic areas.

Rhea-AI Summary

Lineage Cell Therapeutics (LCTX) reported third-quarter 2026 net income of $4.2 million, primarily driven by noncash warrant liability remeasurement. Basic earnings per share were $0.02, while diluted loss per share was $0.03. Revenue fell to approximately $1.5 million from $3.7 million a year earlier; operating loss widened to $7.3 million from $3.8 million. Cash, cash equivalents and marketable securities totaled $45.2 million at September 30, which the company expects to fund planned operations into Q2 2028.

Lineage completed its acquisition of NeuroAirmid Therapeutics on November 12, adding HUNT1, a Huntington’s disease cell therapy in a Phase 1b/2a trial. Six patients have been dosed, with no significant serious adverse events reported. A U.S. patent covering AlloSCOPE 5D manufacturing technology was issued. COR1 advanced into preclinical testing, with initial data expected in Q1 2027; the ReSonance collaboration advanced into its second year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.64%
Tags
-
Rhea-AI Summary

Lineage Cell Therapeutics (LCTX) acquired NeuroAirmid Therapeutics, adding the clinical-stage Huntington’s disease cell therapy HUNT1 to its development pipeline.

The acquisition includes certain worldwide program rights and use of REGEN4HD study data. The enrolling Phase 1b/2a trial has dosed 6 patients and plans to enroll up to 21. Closing consideration was approximately $4.7 million, half cash and half stock. Investors are eligible for up to $5 million on the first closing anniversary, up to $48 million in development, regulatory and clinical milestones, and a minimum low seven-figure payment upon a possible future licensing transaction.

Lineage assumes estimated clinical costs of $3.1 million through February 2030, subsequent clinical development and future manufacturing activities. CIRM funds most ongoing study costs. Lineage plans to transfer HUNT1 production to its AlloSCOPE manufacturing platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.64%
Tags
-
Rhea-AI Summary

Lineage Cell Therapeutics (LCTX) will report third-quarter 2026 financial and operating results on November 12, 2026, after U.S. markets close. Management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the results and provide a business update. A webcast replay will remain available on the company’s website for 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.55%
Tags
earnings date
Rhea-AI Summary

Lineage Cell Therapeutics (LCTX) advanced its ReSonance hearing-loss program into the second year of its collaboration with William Demant Invest. All planned first-year preclinical development activities were completed, and the joint scientific committee approved advancement. WDI agreed to fund up to $12 million in collaboration costs over three years beginning August 2025.

Lineage completed its first batch of current Good Manufacturing Practice-grade material, three engineering manufacturing runs and an internal manufacturing technology transfer. The partners established a preclinical deafening model for functional testing. A Danish Medicines Agency meeting in Q4 2026 is scheduled to discuss development plans and seek scientific advice. The collaboration supports a potential application to begin clinical trials. Lineage plans further laboratory and animal characterization and presentations of preclinical results during 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
none
-
Rhea-AI Summary

Lineage Cell Therapeutics (LCTX) received U.S. Patent No. 12,692,476 covering its AlloSCOPE cell manufacturing platform, including its AlloSCOPE 5D technology, with an expected expiration of June 9, 2043.

The patent covers methods for producing high-volume, low-passage, undifferentiated and genetically stable pluripotent stem cells designed to respond synchronously to differentiation cues. AlloSCOPE 5D combines 2D-like growth on microcarriers within a 3D bioreactor to seek the control and reproducibility of 2D systems with the scale and automation of 3D culture, aiming to reduce handling and aseptic risk. Lineage believes this approach can support commercially feasible production for high-dose indications, including potential billion-cell-per-patient applications such as Type 1 Diabetes, and is already using AlloSCOPE 5D in its COR1 corneal program while planning to deploy it toward ILT1.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
none
-
Rhea-AI Summary

Lineage Cell Therapeutics (NYSE American/TASE: LCTX) reported second quarter 2026 revenue of $1.1 million, down $1.7 million year over year, and total operating expenses of $10.0 million, down from $22.5 million mainly due to a prior-year VAC platform impairment. Loss from operations was $8.9 million, while other income of $10.5 million related primarily to non-cash warrant liability remeasurement contributed to net income of $1.5 million versus a $30.5 million loss a year ago. Cash, cash equivalents, and marketable securities totaled $50.8 million at June 30, 2026, which the company expects to fund operations into Q3 2028.

Lineage highlighted 3‑year Phase 1/2a OpRegen (RG6501) data with sustained BCVA gains and retinal structural changes, progress on its wholly owned corneal program COR1, ongoing enrollment in the OPC1 DOSED spinal cord injury study, advancement of the ReSonance (ANP1) hearing loss collaboration, scale-up under the ILT1 manufacturing initiative, and formation of a Scientific Advisory Board with Joachim Fruebis, PhD as founding member.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.65%
Tags
Rhea-AI Summary

Lineage Cell Therapeutics (NYSE American/TASE: LCTX) will report its second quarter 2026 financial and operating results on August 6, 2026, after the U.S. market close, and will host a conference call and webcast at 4:30 p.m. ET / 1:30 p.m. PT.

Investors can join by dialing (800) 715-9871 in the U.S. and Canada using Conference ID 2355043, or via a live webcast in the Investors section of the company’s website. A webcast replay will be available for 30 days, and a telephone replay at (800) 770-2030 through August 13, 2026. Lineage is a clinical-stage biotechnology company developing allogeneic “off the shelf” cell therapies via its AlloSCOPE platform, with programs including OpRegen, OPC1, ReSonance (ANP1), PNC1, RND1, ILT1, and COR1.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.72%
Tags
earnings date
-
Rhea-AI Summary

Lineage Cell Therapeutics (NYSE American, TASE: LCTX) provided an update on COR1, its allogeneic corneal endothelial cell (CEnC) transplant program for corneal endothelial disease, currently in preclinical development. COR1 uses a pluripotent cell-derived, “off the shelf” CEnC supply intended to address limitations of cadaver-derived donor cells such as restricted supply, variable quality, complex handling, and short shelf-life.

According to the company, COR1 is manufactured via the proprietary AlloSCOPE 5D platform, enabling bioreactor-based expansion and differentiation and a cryopreserved “thaw and inject” formulation for immediate use and long-term storage. Lineage reports that COR1 currently meets internal thresholds for potency, identity and scale, is being advanced into in-vivo animal testing with initial data expected this year, and that a two-tiered GMP banking system may be capable of generating millions of final product doses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.47%
Tags
none
-
Rhea-AI Summary

Lineage Cell Therapeutics (NYSE American:LCTX) announced that CEO Brian M. Culley will participate in a fireside chat at the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit on July 16, 2026, at the InterContinental Boston hotel.

Investor meetings are available by invitation through B. Riley Securities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.48%
Tags
none
Rhea-AI Summary

Lineage Cell Therapeutics (NYSE American:LCTX) reported Q1 2026 results and a broad business update.

Revenue rose to $1.7M, with a net loss of $4.8M, and cash of $53.4M expected to fund operations into Q2 2028. Key updates included positive 3‑year RG6501 OpRegen Phase 1/2a data, continued Phase 2a GAlette enrollment with Roche/Genentech, treatment of a second chronic SCI patient in the OPC1 DOSED study, launch of COR1 for corneal endothelial disease, and the first milestone in the AlloSCOPE 5D/ILT1 manufacturing initiative. The company also advanced its ReSonance (ANP1) hearing loss program under a WDI collaboration, formed a Scientific Advisory Board led by Joachim Fruebis, PhD, and appointed Priyantha Herath, MD, PhD, as Senior Vice President & Head of Clinical.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.76%
Tags

FAQ

What is the current stock price of Lineage Cell Therapeutics (LCTX)?

Lineage Cell Therapeutics (LCTX) last closed at $0.7719.

What is the market cap of Lineage Cell Therapeutics (LCTX)?

The market cap of Lineage Cell Therapeutics (LCTX) is approximately $195.3M.